phloroglucinol has been researched along with Mood Disorders in 2 studies
Phloroglucinol: A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent.
phloroglucinol : A benzenetriol with hydroxy groups at position 1, 3 and 5.
Mood Disorders: Those disorders that have a disturbance in mood as their predominant feature.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to conduct a comprehensive review of kava and SJW, to review any evidence of efficacy, mode of action, pharmacokinetics, safety and use in major depressive disorder, bipolar disorder, seasonal affective disorder (SAD), generalized anxiety disorder, social phobia (SP), panic disorder (PD), obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD)." | 8.85 | Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. ( Kavanagh, DJ; Sarris, J, 2009) |
| "The objective of this study was to conduct a comprehensive review of kava and SJW, to review any evidence of efficacy, mode of action, pharmacokinetics, safety and use in major depressive disorder, bipolar disorder, seasonal affective disorder (SAD), generalized anxiety disorder, social phobia (SP), panic disorder (PD), obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD)." | 4.85 | Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. ( Kavanagh, DJ; Sarris, J, 2009) |
| "Hyperforin was intragastric administrated on the 21th day after birth, and lasted for 2 weeks in ESP+Hyp group." | 1.42 | Hyperforin alleviates mood deficits of adult rats suffered from early separation. ( Liu, C; Qin, X; Yang, Z; Zhu, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, M | 1 |
| Liu, C | 1 |
| Qin, X | 1 |
| Yang, Z | 1 |
| Sarris, J | 1 |
| Kavanagh, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia[NCT04420260] | 152 participants (Actual) | Interventional | 2021-03-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for phloroglucinol and Mood Disorders
| Article | Year |
|---|---|
Kava and St. John's Wort: current evidence for use in mood and anxiety disorders.
Topics: Anthracenes; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Bridged Bicyclo Compounds; Humans; | 2009 |
1 other study available for phloroglucinol and Mood Disorders
| Article | Year |
|---|---|
Hyperforin alleviates mood deficits of adult rats suffered from early separation.
Topics: Animals; Antidepressive Agents; Exploratory Behavior; Feeding Behavior; Female; Maternal Deprivation | 2015 |